Effect of Pancrelipase Therapy on Exocrine Pancreatic Insufficiency Symptoms and Coefficient of Fat Absorption Associated With Chronic Pancreatitis.
Abdominal Pain
/ drug therapy
Adolescent
Adult
Aged
Defecation
/ drug effects
Exocrine Pancreatic Insufficiency
/ diagnosis
Feces
Female
Flatulence
/ drug therapy
Gastrointestinal Agents
/ adverse effects
Humans
Intestinal Absorption
/ drug effects
Lipid Metabolism
/ drug effects
Male
Middle Aged
Pancreatitis, Chronic
/ diagnosis
Pancrelipase
/ adverse effects
Randomized Controlled Trials as Topic
Time Factors
Treatment Outcome
Young Adult
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
10
2
2021
medline:
15
12
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
The aim of this study was to evaluate whether improvement in coefficient of fat absorption (CFA) with pancreatic enzyme replacement therapy correlates with clinical symptoms in patients with chronic pancreatitis with moderate to severe exocrine pancreatic insufficiency. Data were pooled from 2 randomized double-blind trials of the effects of 1 week of pancrelipase (n = 59) versus placebo (n = 57) on CFA and stool frequency, stool consistency, abdominal pain, and flatulence; 1 trial included a 51-week open-label pancrelipase treatment period (n = 34). Compared with placebo, significantly more patients receiving pancrelipase reported decreased stool frequency at week 1 (72% vs 38%; P < 0.001). Although 30% of patients receiving pancrelipase and 20% receiving placebo reported improved stool consistency, changes in stool consistency, abdominal pain, and flatulence were not different between groups. Mean CFA absolute change from baseline was significantly greater with pancrelipase versus placebo (24.7% vs 6.4%; P < 0.001). Improvements in stool consistency and frequency correlated with CFA improvement. Symptom improvements persisted or further improved through 52 weeks of treatment. Pancrelipase significantly improved exocrine pancreatic insufficiency maldigestive symptoms. Improvements in objective stool symptoms with pancreatic enzyme replacement therapy correlated with CFA improvement at 1 week.
Identifiants
pubmed: 33560089
doi: 10.1097/MPA.0000000000001733
pii: 00006676-202102000-00008
doi:
Substances chimiques
Gastrointestinal Agents
0
Pancrelipase
53608-75-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-182Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut . 2005;54(suppl 6):vi1–vi28.
Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract . 2018;72:e13066.
Pezzilli R, Andriulli A, Bassi C, et al. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. World J Gastroenterol . 2013;19:7930–7946.
de la Iglesia-Garcia D, Vallejo-Senra N, Iglesias-Garcia J, et al. Increased risk of mortality associated with pancreatic exocrine insufficiency in patients with chronic pancreatitis. J Clin Gastroenterol . 2018;52:e63–e72.
Capurso G, Traini M, Piciucchi M, et al. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol . 2019;12:129–139.
Layer P, Kashirskaya N, Gubergrits N. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. World J Gastroenterol . 2019;25:2430–2441.
Thorat V, Reddy N, Bhatia S, et al. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis—a double-blind, placebo-controlled study. Aliment Pharmacol Ther . 2012;36:426–436.
Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol . 2010;105:2276–2286.
Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol . 2013;19:7258–7266.
Pongprasobchai S. Maldigestion from pancreatic exocrine insufficiency. J Gastroenterol Hepatol . 2013;28 Suppl 4:99–102.
Petersen JM, Forsmark CE. Chronic pancreatitis and maldigestion. Semin Gastrointest Dis . 2002;13:191–199.
Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol . 2011;26 Suppl 2:12–16.
Durie P, Baillargeon JD, Bouchard S, et al. Diagnosis and management of pancreatic exocrine insufficiency (PEI) in primary care: consensus guidance of a Canadian expert panel. Curr Med Res Opin . 2017;34:25–33.
Keller J, Layer P. Diagnosis of pancreatic exocrine insufficiency in chronic pancreatitis. The Pancreapedia: Exocrine Pancreas Knowledge Base. September 14, 2015. Available at: http://www.pancreapedia.org/reviews/diagnosis-of-pancreatic-exocrine-insufficiency-in-chronic-pancreatitis . Accessed January 30, 2017.
Fogel EL, Shahda S, Sandrasegaran K, et al. A multidisciplinary approach to pancreas cancer in 2016: a review. Am J Gastroenterol . 2017;112:537–554.
Safdi M, Bekal PK, Martin S, et al. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas . 2006;33:156–162.
de la Iglesia-García D, Huang W, Szatmary P, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut . 2017;66:1354–1355.
Toskes PP, Secci A, Thieroff-Ekerdt R, et al. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis. Pancreas . 2011;40:376–382.
Gubergrits N, Malecka-Panas E, Lehman GA, et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther . 2011;33:1152–1161.
D'Haese JG, Ceyhan GO, Demir IE, et al. Pancreatic enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis: a 1-year disease management study on symptom control and quality of life. Pancreas . 2014;43:834–841.
Armbrecht U, Svanvik J, Stockbrügger R. Enzyme substitution in chronic pancreatitis: effects on clinical and functional parameters and on the hydrogen (H2) breath test. Scand J Gastroenterol Suppl . 1986;126:55–59.
Pap A, Varró V. Replacement therapy in pancreatic insufficiency with a new pancreatin preparation respecting the physiological ratio of lipase/trypsin activity. Hepatogastroenterology . 1988;35:83–86.
Jørgensen BB, Pedersen NT, Worning H. Monitoring the effect of substitution therapy in patients with exocrine pancreatic insufficiency. Scand J Gastroenterol . 1991;26:321–326.
Suarez F, Levitt MD, Adshead J, et al. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci . 1999;44:1317–1321.
Dominguez-Munoz JE, Drewes AM, Lindkvist B, et al. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. Pancreatology . 2018;18:847–854.
Frulloni L, Falconi M, Gabbrielli A, et al. Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis . 2010;42(suppl 6):S381–S406.